You just read:

BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors

News provided by

BerGenBio ASA

15 Jan, 2020, 16:31 GMT